Capstone Asset Management’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q2 | $341K | Buy |
4,509
+160
| +4% | +$12.1K | 0.01% | 1156 |
|
|
2017
Q1 | $287K | Buy |
4,349
+192
| +5% | +$12.7K | 0.01% | 1324 |
|
|
2016
Q4 | $263K | Sell |
4,157
-3,398
| -45% | -$215K | 0.01% | 1405 |
|
|
2016
Q3 | $481K | Sell |
7,555
-353
| -4% | -$22.5K | 0.01% | 982 |
|
|
2016
Q2 | $588K | Buy |
7,908
+1,812
| +30% | +$135K | 0.02% | 823 |
|
|
2016
Q1 | $407K | Buy |
6,096
+368
| +6% | +$24.6K | 0.01% | 1051 |
|
|
2015
Q4 | $387K | Buy |
5,728
+1,390
| +32% | +$93.9K | 0.01% | 1094 |
|
|
2015
Q3 | $232K | Buy |
4,338
+161
| +4% | +$8.61K | 0.01% | 1399 |
|
|
2015
Q2 | $263K | Sell |
4,177
-797
| -16% | -$50.2K | 0.01% | 1375 |
|
|
2015
Q1 | $239K | Buy |
+4,974
| New | +$239K | 0.01% | 1503 |
|
|
2014
Q3 | – | Sell |
-5,375
| Closed | -$209K | – | 1658 |
|
|
2014
Q2 | $209K | Sell |
5,375
-229
| -4% | -$8.9K | 0.01% | 1569 |
|
|
2014
Q1 | $235K | Sell |
5,604
-4,985
| -47% | -$209K | 0.01% | 1568 |
|
|
2013
Q4 | $347K | Buy |
+10,589
| New | +$347K | 0.01% | 1409 |
|